Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced the launch of Tapestri Designer, the first-ever automated, cloud-based tool for designing targeted single-cell DNA custom panels. The easy to use, self-service interface reduces design time for custom panels from weeks to just minutes, extending the Tapestri Platform into the only customizable single-cell DNA targeted solution for high impact applications. The company also announced its expansion into Europe, rolling out regional sales alongside partnerships with three key research institutions: VIB in Flanders, Belgium, the Cancer Research Center of Toulouse, France, and Saint-Louis Hospital in Paris, France.
When studying genomic heterogeneity at the single-cell level, customization offers flexibility to target the relevant regions of interest, maximize data quality for those regions and then tailor sequencing budgets and analysis time. With Tapestri Single-Cell DNA Targeted Custom Panels, researchers and clinicians have unparalleled flexibility to focus on 10s to 100s of impactful genetic mutations over 1000s of cells without sacrificing data quality. Furthermore, targeted custom panels dramatically reduce the high cost that is often associated with single-cell experiments while keeping analysis simple and cost-effective, enabling routine adoption of single-cell sequencing.
The traditional customization process is manual and iterative, requiring the work of a skilled bioinformatician, and taking anywhere from weeks to even months to finalize. Tapestri Designer simplifies customization with the first cloud-based platform that enables customers to easily create custom panels in minutes. The simple intuitive interface of Tapestri Designer allows researchers to complete custom designs with three easy steps:
- Set-up an account
- Upload a CSV file or enter a gene, ID, or coordinate targets
- Submit a design to receive results within minutes
The launch of the product is the first in a larger effort by Mission Bio to incorporate artificial intelligence and machine learning algorithms into the Tapestri Platform. With dynamic improvements to panel design and performance through Tapestri Designer, Mission Bio continues to advance the understanding of disease to guide research and patient care.
“You can think of Tapestri Designer as the 3D printer for single-cell DNA panels,” explained Charlie Silver, co-founder and CEO of Mission Bio. “What once took weeks or months and a bioinformatician is now a self-service cloud platform that can be used by research teams to create panels tailored to specific experiments and needs, all on-demand. This automated capability cuts out the middleman, streamlining the process and empowering researchers to improve their understanding of cancer, inform treatment options, and, ultimately, save patient lives.”
In addition to unlocking pent-up demand for custom panels, Mission Bio has expanded regional sales into Europe to meet burgeoning international interest. Mission Bio secured partnerships with three key research institutions: VIB, a leading research institute in Flanders, Belgium and an early adopter of breakthrough technologies; the Cancer Research Center of Toulouse, one of the largest biobanks of cancer samples in France; and Saint-Louis Hospital in Paris, one of the most advanced hematology teaching hospitals in Europe. The company's partnerships with a key European research institutions will enable it to scale Tapestri's footprint, empowering researchers to deliver on the promise of precision medicine, worldwide.
“We are excited to add the Tapestri Platform to our Single-Cell Accelerator Program. This technology now allows us to profile mutational heterogeneity at the single-cell level which is essential to unlock the secrets of cancer progression and therapy resistance,” said Toon Swings, Life Science Technology Specialist at VIB Tech Watch and project lead for the implementation of the Mission Bio technology. “Tapestri Designer is pioneering to the whole single-cell field. It is incredibly easy to use, and it has significantly reduced our design turnaround time. This is essential as we plan to run several custom panels across a variety of cancer indications on the Tapestri Platform.”
This news comes on the heels of a landmark 2018 for Mission Bio, which recently announced $30 million in Series B funding from notable investors Agilent Technologies (NYSE: A), Cota Capital, LAM Capital, and Mayfield to scale its Tapestri Platform into even more markets.
To learn more about Mission Bio and how it's moving precision medicine forward, visit www.missionbio.com.
About Mission Bio
Mission Bio helps researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine with Tapestri, the Precision Genomics Platform. Tapestri provides industry-first single-cell DNA analysis capability to enable the accelerated and accessible detection of genetic heterogeneity within and across cells populations for applications in oncology, immunology, and genome editing. The platform includes an instrument, consumables and software, which plug seamlessly into existing NGS workflows. The company's Tapestri Platform was honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. Additional studies in therapy resistance and Minimal Residual Disease (MRD) using Tapestri have been reported by other leading cancer centers, including the University of California, San Francisco, University of Pennsylvania, and Stanford University. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.
— WebWireID237020 —